Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $31.74 USD
Change Today -0.43 / -1.34%
Volume 226.7K
RTRX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

retrophin inc (RTRX) Snapshot

Open
$32.21
Previous Close
$32.17
Day High
$32.96
Day Low
$31.59
52 Week High
07/16/15 - $36.46
52 Week Low
10/1/14 - $7.85
Market Cap
1.1B
Average Volume 10 Days
279.8K
EPS TTM
$-2.95
Shares Outstanding
35.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RETROPHIN INC (RTRX)

retrophin inc (RTRX) Details

Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious, catastrophic, or rare diseases. Its product line includes Cholbam, a cholic acid for the treatment of bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of peroxisomal disorders, such as Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea, or complications from decreased fat soluble vitamin absorption; Thiola, which is indicated for the prevention of cystine stone formation in patients with severe homozygous cystinuria with urinary cystine greater than 500 mg/day, who are resistant to treatment with conservative measures of high fluid intake, alkali and diet modification, or who have adverse reactions to d-penicillamine; and Chenodal, a synthetic oral form of chenodeoxycholic acid for radiolucent stones in well-opacifying gallbladders. The company’s product pipeline also includes compounds for various catastrophic diseases, including focal segmental glomerulosclerosis, pantothenate kinase-associated neurodegeneration, infantile spasms, nephrotic syndrome, and others. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.

120 Employees
Last Reported Date: 05/11/15
Founded in 2011

retrophin inc (RTRX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $323.2K
Executive Vice President of Research and Deve...
Total Annual Compensation: $430.8K
General Counsel and Secretary
Total Annual Compensation: $95.8K
Compensation as of Fiscal Year 2014.

retrophin inc (RTRX) Key Developments

Retrophin, Inc. Pays $47.3 Million as Payment in Full for All Principal and Accrued Interest Under Certain Credit Agreement

Retrophin, Inc. paid $47.3 million as payment in full for all principal and accrued interest under that certain credit agreement, dated as of June 30, 2014, and amended on July 16, 2014, November 13, 2014, January 12, 2015 and March 24, 2015, among the company, the lenders from time to time party thereto and U.S. Bank National Association. The amount paid was inclusive of a $2.25 million prepayment premium, as required by the terms of the credit agreement. Upon receipt of this final payment, the liens and security interests granted pursuant to the credit agreement and the documents executed and delivered pursuant thereto or in connection therewith (collectively, the loan documents) were automatically and irrevocably released and terminated, and the loan documents were permanently terminated.

Retrophin, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 02:00 PM

Retrophin, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 02:00 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Stephen J. Aselage, Chief Executive Officer, President and Director.

Retrophin, Inc. Reports Consolidated Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Retrophin, Inc. reported consolidated unaudited earnings results for the first quarter ended March 31, 2015. Non-GAAP operating income for the first quarter 2015 was $1.4 million compared to a non-GAAP operating loss of $17.5 million for the same period in 2014. Net income for the first quarter of 2015 was $39.7 million or $1.32 diluted per share on a GAAP basis compared to a net loss of $75.7 million or $3.25 diluted per share for the same period in 2014. Non-GAAP adjusted net loss for the first quarter of 2015 was $1.1 million or $0.04 per share compared to $17.5 million or $0.75 per share for the same period in 2014. Net product sales were $17,371,800 against $27,900 a year ago. Operating loss was $8,104,443 against $22,061,669 a year ago. Loss before income taxes was $366,162 against $75,670,271 a year ago. Non-GAAP net loss was $1,076,200 or $0.04 diluted per share against $17,527,457 or $0.75 diluted per share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RTRX:US $31.74 USD -0.43

RTRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioMarin Pharmaceutical Inc $146.27 USD +1.71
GlaxoSmithKline PLC 1,396 GBp +7.00
Pfizer Inc $36.06 USD +0.33
Shire PLC 5,680 GBp +90.00
View Industry Companies
 

Industry Analysis

RTRX

Industry Average

Valuation RTRX Industry Range
Price/Earnings 100.0x
Price/Sales 19.2x
Price/Book 6.7x
Price/Cash Flow 253.4x
TEV/Sales 20.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RETROPHIN INC, please visit www.retrophin.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.